Artemis Medicare Services Limited
₹292.20-₹6.00 (-2.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹4,059 Cr
- P/E
- 42.6x
- EV / EBITDA
- 32.0x
- Revenue
- ₹913 Cr
- Net margin
- 5.8%
- ROCE
- 16.9%
Price chart
Technical chartScreen technicals →+15.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -15.5%
- 3M
- -3.5%
- 6M
- +19.5%
- 1Y
- +15.8%
- 5Y
- +728.9%
52-week range
Day change -₹6.00 (-2.0%) from ₹298 to ₹292 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ARTEMISMED, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 19.6%
Concerns1
- Negative free cash flow (₹249 Cr)
Rule-based from financial data. Not advice.
About the company
Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services.
Read moreShow less
Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services. It also offers billing and insurance, childcare, emotional and support program, full body checkup, international patient, medical interpreter and record, mind body medicine, nursing, nutrition, patient and family advisory, patient advocacy and portal, pre-admission testing, and smoking cessation program services, as well as home care services. Artemis Medicare Services Limited was incorporated in 2004 and is based in Gurugram, India.
- Sector
- Healthcare
- Shares outstanding
- 15.9 Cr shares
- ISIN
- INE025R01021
- BSE code
- 542919
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹4,059 Cr
- P/E
- 42.6x
- P/B
- 4.0x
- EV / EBITDA
- 32.0x
- EV / Sales
- 5.1x
- P/S
- 4.8x
- Earnings yield
- 2.3%
- 52-week high
- ₹366.35
- 52-week low
- ₹205.25
Profitability
- Operating margin
- 15.1%
- Net margin
- 5.8%
- EBITDA margin
- 16.0%
- ROE
- 10.8%
- ROCE
- 16.9%
- ROA
- 5.2%
- Dividend payout
- 12.0%
- Tax rate
- 28.0%
- Other income, % of PBT
- 10.3%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹913 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹135 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 33.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 69.4%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.6%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹108 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -16.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹28.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.5%
Solvency and efficiency
- Current ratio
- 1.13
- Debt / Equity
- 0.67
- Debt / Assets
- 0.32
- Debt / EBITDA
- 2.26
- Interest coverage
- 4.27
- Financial leverage
- 2.10
- CFO / Net profit
- 2.20
- Cash / Market cap
- 4.9%
- Cash per share
- ₹12.61
- Asset turnover
- 0.89
- Fixed asset turnover
- 1.21
- Capital intensity
- 0.83
- Debtor days
- 36 days
- Cash conversion cycle
- 36 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹913 Cr |
| Expenses | ₹763 Cr |
| Operating profit | ₹150 Cr |
| Other income | ₹33 Cr |
| Interest | ₹30 Cr |
| Depreciation | ₹43 Cr |
| Profit before tax | ₹109 Cr |
| Tax and other | ₹26 Cr |
| Net profit | ₹83 Cr |
Revenue and net profit
Revenue grew 8.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹402 Cr | ₹7 Cr |
| FY2022 | ₹545 Cr | ₹33 Cr |
| FY2023 | ₹714 Cr | ₹40 Cr |
| FY2024 | ₹845 Cr | ₹49 Cr |
| FY2025 | ₹913 Cr | ₹83 Cr |
Cash flows
FY2025: ₹139 Cr from operations, -₹249 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹27 Cr | -₹7 Cr |
| FY2022 | ₹61 Cr | -₹45 Cr |
| FY2023 | ₹129 Cr | -₹24 Cr |
| FY2024 | ₹108 Cr | ₹18 Cr |
| FY2025 | ₹139 Cr | -₹249 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹913 Cr+8.0%1Y
- Net profit
- ₹83 Cr+69.4%1Y
- Cash from operations
- ₹139 Cr
- Free cash flow
- -₹249 Cr-1,483.3%1Y
- Revenue CAGR, 5Y
- 8.5%
- EBITDA CAGR, 5Y
- 15.4%
- Net profit CAGR, 5Y
- 19.6%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹913 Cr | ₹150 Cr | — | ₹83 Cr | ₹139 Cr | -₹249 Cr | 9.9% | +8.0% | +69.4% |
Monthly returns
Month-by-month returns of ARTEMISMED across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,343 Cr |
| Equity capital | ₹14 Cr |
| Reserves | ₹828 Cr |
| Borrowings | ₹280 Cr |
| Other liabilities | ₹221 Cr |
| Assets | ₹1,343 Cr |
| Fixed assets | ₹729 Cr |
| Capital work in progress | ₹40 Cr |
| Investments | ₹15 Cr |
| Other assets | ₹559 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ARTEMISMED trades at 42.6x earnings against a peer median of 52.6x (a 19% discount).
Not shown (no positive earnings and no EV / Sales): Sun Pharma Advanced Research Company Ltd., Dishman Carbogen Amcis Limited.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Artemis Medicare Services LimitedARTEMISMEDthis companyP/E ↓ discount | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Sun Pharma Advanced Research Company Ltd.SPARC | ₹4,415 Cr | — | -12.6x | -312.9% | -11.7x |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| RPG Life Sciences LimitedRPGLIFE | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| SENORES PHARMACEUTICALS LIMITEDSENORES | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ARTEMISMED since 1 January, against earlier years.
Historical volatility
ARTEMISMED's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 9.0% |
| FY2022 | 12.0% |
| FY2023 | 13.0% |
| FY2024 | 15.0% |
| FY2025 | 16.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹913 Cr |
| Costs | |
| Interest | ₹30 Cr |
| Expenses | ₹763 Cr |
| Operating profitOperating Profit | ₹150 Cr |
| Other income and charges | |
| Profit before tax | ₹109 Cr |
| Tax | |
| Net profitNet Profit | ₹83 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,343 Cr |
| Equity capitalEquity Capital | ₹14 Cr |
| Reserves | ₹828 Cr |
| Borrowings | ₹280 Cr |
| Other liabilitiesOther Liabilities | ₹221 Cr |
| AssetsTotal Assets | ₹1,343 Cr |
| Fixed assetsFixed Assets | ₹729 Cr |
| Capital work in progressCWIP | ₹40 Cr |
| Investments | ₹15 Cr |
| Other assetsOther Assets | ₹559 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹139 Cr |
| Investing cash flowCash from Investing Activity | -₹388 Cr |
| Financing cash flowCash from Financing Activity | ₹277 Cr |
| Change in cashNet Cash Flow | ₹28 Cr |
Learn while you research
Academy chapters picked for Artemis Medicare Services Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 42.6, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read